drugset / Trial / NCT06937411
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DC-853 in Healthy Participants
RandomizedSequentialDouble-blindBasic science
Summary
The main purpose of this study is to assess the safety and tolerability of LY4100511 (DC-853) after single and multiple dose administrations in healthy participants. Participation could last up to 7 weeks
Timeline
- Start
- 2023-02-13
- Primary completion
- 2023-10-30
- Completion
- 2023-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY4100511 | Unknown | — | Oral |
Indications
No indication recorded.